Dermatology Clinic, Maggiore Hospital, University of Trieste, Piazza dell'Ospitale 1, 34129, Trieste, Italy.
Plastic and Reconstructive Surgery Department, Campus Biomedico University, Rome, Italy.
Curr Treat Options Oncol. 2021 Mar 16;22(4):35. doi: 10.1007/s11864-021-00826-3.
Recently introduced systemic therapies for locally advanced and metastatic non-melanoma skin cancers (NMSCs) are paving the way for neoadjuvant approach. Although none of the therapeutic options has currently gained indication in this setting, neoadjuvant approach for NMSCs is an open field and we are likely to see huge developments in the near future. Targeted therapy with sonic hedgehog pathway inhibitors is very effective in locally advanced or multiple basal cell carcinomas while immunotherapy with immune checkpoint inhibitors appears to be promising for advanced cutaneous squamous cell carcinoma and Merkel cell carcinoma. To date, targeted therapy and immunotherapy represent the frontiers in NMSC therapeutic management and, according to recent studies, good results can be achieved.
最近引入的局部晚期和转移性非黑色素瘤皮肤癌（NMSC）的系统治疗方法为新辅助方法铺平了道路。尽管目前尚无治疗选择在这种情况下获得适应证，但 NMSC 的新辅助方法是一个开放的领域，我们可能会在不久的将来看到巨大的发展。针对 sonic hedgehog 通路抑制剂的靶向治疗在局部晚期或多发性基底细胞癌中非常有效，而免疫检查点抑制剂的免疫治疗似乎对晚期皮肤鳞状细胞癌和 Merkel 细胞癌有前途。迄今为止，靶向治疗和免疫治疗代表了 NMSC 治疗管理的前沿，根据最近的研究，可以取得良好的效果。
